Alston & Bird client Larkspur Health Acquisition Corp., a blank-check special purpose acquisition company, has completed its business combination with ZyVersa Therapeutics Inc., a clinical stage specialty biopharmaceutical company, in a transaction valued at $108.92 million.
Representing Larkspur was an Alston & Bird team led by partners Matt Mamak and Stuart Rogers, senior associate Robyn Downing, and associates Misbah Mohiuddin, Siena Cornacchini, and Steven Chen (Corporate & Business Transactions).
Representing Larkspur was an Alston & Bird team led by partners Matt Mamak and Stuart Rogers, senior associate Robyn Downing, and associates Misbah Mohiuddin, Siena Cornacchini, and Steven Chen (Corporate & Business Transactions).